Please login to the form below
Gavin Giovannoni
This page shows the latest Gavin Giovannoni news and features for those working in and with pharma, biotech and healthcare.
Merck Serono's MS drug approved in Russia
We expect other regulatory approvals in the near future.". Gavin Giovannoni of the UK's Blizard Institute of Cell and Molecular Science and principal investigator of CLARITY, said the approval will
Latest news
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
The role of brain health in treating MS
Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health, the ... Rather than treating and reducing relapses, top
-
Blue Latitude Health
Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health, the
Blue Latitude Health
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Assessing the value of interim analyses in clinical trials
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- AZ’s Imfinzi combination shows promise in liver cancer
- Gilead’s Trodelvy set for EU approval in breast cancer
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Novo Nordisk settles US insulin pricing dispute for $100m
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- bluebird bio provides update on 2seventy bio spin-off
- Amgen strikes $240m autoimmune deal with Evoq Therapeutics
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
